Who founded Iambic Therapeutics, Inc.?

Iambic Therapeutics, Inc. was founded by Fred Manby, Thomas Miller in 2019.

Who are Iambic Therapeutics, Inc.'s investors?

Iambic Therapeutics, Inc.'s investors include Abingworth, Nexus Venture Partners, Nexus Ventures.

How much funding has Iambic Therapeutics, Inc. raised?

Iambic Therapeutics, Inc. has disclosed $334.6M raised across 5 rounds.

Where is Iambic Therapeutics, Inc. headquartered?

Iambic Therapeutics, Inc. is headquartered in San Diego, US.

Iambic Therapeutics, Inc.

San Diego, US · Founded 2019 · Delaware corporation · 3 known investors

Find your way into Iambic Therapeutics, Inc.

1,349 people in our graph share verified history with the Iambic Therapeutics, Inc. team — schools, employers, funds. One of them is your warm intro.

Charles Callunlockedknows Pete Olson · together at University of California, Davis (overlapped)

×4knows the team · via Massachusetts Institute of Technology

×4knows the team · via University of Oxford

knows the team · via UCL

knows the team · via UC Berkeley

knows the team · via Princeton University

Biotech

Founders & leadership

Iambic Therapeutics, Inc. was founded in 2019 by Fred Manby and Thomas Miller.

Fred ManbyinCo-founderCo-Founder & CTO at Iambic

Thomas Miller inCo-founderThomas Miller holds a Ph.D. in theoretical chemistry from Oxford University and a B.S. in chemistry and mathematics from Texas A&M University. He spent over a decade as a tenured professor at Caltech before co-founding Iambic Therapeutics in 2020, where he serves as CEO of the clinical-stage biotech company developing AI-driven drug discovery approaches.

Neil JosephsoninExecutiveChief Medical Officer at Iambic

Michael Secora inExecutiveMichael Secora is an executive officer at Iambic Therapeutics, a company focused on therapeutic development. He has backgrounds in science and investing.

Pete Olson inExecutivePete Olson holds a PhD and serves as Chief Scientific Officer at Iambic Therapeutics, a clinical-stage biotech company developing AI-enabled drug discovery platforms. He previously held the role of VP, Research at Mirati Therapeutics (acquired by Bristol Myers Squibb in 2024), where he directed biology and pharmacology functions for small-molecule oncology programs, and before that was a Senior Group Leader at Pfizer Oncology Research, with over 25 years of experience in academic and industry research.

Chao Zhang inExecutiveChao Zhang is co-founder and chief operating officer of NeuShen Therapeutics, a CNS-focused biotech company. He has over 19 years of biopharmaceutical industry experience in R&D, portfolio and project management, holds PMP and PgMP certifications, and has expertise in oncology pharmacology and biomarkers.

Tabbert TengExecutive

Board

Jishnu Bhattacharjee in 𝕏Board directorManaging Director at Nexus Venture Partners

R. Jacob VogelsteinBoard director

Evan RachlinBoard director

Kurt von Emster inBoard directorManaging Partner at Abingworth

William RastetterBoard director

Investors · 3

AbingworthreportedLondon · $15M – $30Mvia Kurt von Emster · board

Nexus Venture PartnersreportedPort Louis, Port Louis · $500K – $10Mvia Jishnu Bhattacharjee · board

Nexus VenturesreportedMenlo Park

Reported raises · per SEC filings

Form D private placements

$334.6M disclosed across 5 rounds · 2023–2026

▶$66MraisedSep 2026 · 16 investors · Biotechnology

Rule 506(b)